Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anagrelide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 20/20 | 0.97 |
| ▸ | PDE3A known ✓ | Q14432 | 20/20 | 0.97 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | PDE2A | O00408 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anagrelide SCHEMBL729172 | 0.99 | PDE3B (0.94) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9411 | 0.99 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL5060881 | 0.99 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL29491059 | 0.99 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL318593 | 0.97 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1449704 | 0.97 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9046734 | 0.97 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL16335881 | 0.92 | PDE3B (0.87) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1664162 | 0.91 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL28341325 | 0.91 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9750698-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9381198-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160051552-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | disclosed |
| CN-102123699-A | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR INC | 2011-07-13 | — | — | CN | disclosed |
| EP-2306985-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | Biovascular, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010005480-A9 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | PF4, PLAT, VASP | PDE3B 64/4885PDE3A 50/4885P2RY12 134/4885 |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885P2RY12 147/4885 |
| US-20160051552-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885P2RY12 147/4885 |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885P2RY12 147/4885 |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885P2RY12 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.